Abilify Poor Impulse Control Side Effect

Attorneys serving the South Bay Area and San Francisco including Redondo Beach, Torrance, Manhattan Beach and Nearby Cities

Abilify cases related to gambling and poor impulse control On May 3, 2016, The US Food and Drug Administration (FDA) issued a warning about the use of the antipsychotic drug “aripiprazole,” which is sold under the names Abilify, Abilify Maintena, Aristada and generics. The FDA is warning of certain compulsive or uncontrollable urges that have been reported by some Abilify users, including compulsion related to:

  • Gambling
  • Binge eating
  • Shopping
  • Hypersexuality

The FDA says that these uncontrollable urges were reported to have stopped when use of the potentially dangerous medication was discontinued or when the dosage was reduced. Although the FDA says these impulse-control problems are rare, they acknowledge that, when present, the behavior can harm the person experiencing it.

As a result of the FDA’s warning, on August 20, 2016, the prescription label for Abilify now includes a warning for “pathological gambling and other compulsive behaviors.” The warning notes that patients may not recognize such behaviors as abnormal, counsels physicians to ask about such behaviors and recommends discontinuation or dose reduction if behaviors arise.  It is abundantly clear that the ingestion of Abilify causes pathological gambling.

Our law firm is an experienced team of trial lawyers that focuses on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently accepting new compulsive gambling cases in all 50 states.

Next month, on September 29, 2016, an entity called the US Judicial Panel on Multidistrict Litigation, or JPML, will hear oral arguments to establish pretrial proceedings for all people filing Abilify lawsuits. The attorneys from Kirtland & Packard will be there to advocate for our Abilify clients.

The number of claims from Abilify users is expected to increase. Currently, there are at least 24 such lawsuits in 12 federal court districts across the country. All of these lawsuits involve similar allegations, namely that the drug makers Bristol-Myers Squibb and Otsuka Pharmeceutical Co. failed to warn consumers and the medical community about the risks of impulse-control problems linked to Abilify.

Our California law firm is currently reviewing all claims of poor impulse control and injury related to use of Abilify. For a free consultation, please call 310-536-1000.